期刊文献+

基因重组药物蛋白类杂质检测及质量控制 被引量:1

The test and quality control of protein impurity in gene recombination drugs
下载PDF
导出
摘要 生物技术药物中蛋白类杂质是最普通、最复杂也是最具潜在危害性的杂质,去除生物药品中所有蛋白杂质也是不可能的.为增加产品安全性必须加强对生物制品中蛋白类杂质的质量控制.目前对生物技术药物蛋白类杂质检测及质量控制方法包括:免疫学分析、凝胶电泳、等电聚焦电泳、二维电泳及质谱技术、毛细管电泳、高效液相色谱等.将生物药品中相关蛋白类杂质控制在合理范围内,既可增加用药安全性,又能增强药物生物学活性,是该类药品成功应用于临床的必然要求. Protein impurity is the most common,complex and potentially harmful impurity in bio-technological drugs.Although it is not practical to get rid of all protein impurities in bio-technological drugs,the quality control must be enhanced for the purpose to increase the safety of drugs.Current methods of test and quality control toward protein impurity in bio-technological drugs mainly include immunological analysis,GE(gel electrophoresis),IFE(isoelectric focusing electrophoresis),2-DE(two dimensional electrophoresis),MS(mass spectrometry),CE(capillary electrophoresis),HPLC(High Performance Liquid Chromatography),etc.It is necessary for the successful clinical application of bio-technological drugs to control the protein impurity within an acceptable range,not only because the safety of drugs can be increased,but the biological activity of drugs can be improved.
出处 《辽宁师范大学学报(自然科学版)》 CAS 2012年第4期529-533,共5页 Journal of Liaoning Normal University:Natural Science Edition
基金 国家自然科学基金项目(31071991 31170353)
关键词 生物技术药物 蛋白类杂质 杂质检测 质量控制 bio-technological drug protein impurity impurity test quality control
  • 相关文献

参考文献1

共引文献7

同被引文献26

  • 1徐萍,刘超.胰淀素、胰岛淀粉样蛋白沉积与2型糖尿病[J].医学综述,2005,11(6):500-502. 被引量:3
  • 2金玲,杨慧.α-Synuclein聚集与帕金森病——影响α-synuclein蛋白聚集的因素[J].生物化学与生物物理进展,2006,33(4):321-328. 被引量:11
  • 3FROKJAER S,OTZEN D E. Protein drug stability: a formulation challenge[J]. Nat Rev Drug Discovery, 2005,4.. 298- 306. DOI: 10. 1038/nrd1695.
  • 4WANG W. Protein aggregation and its inhibition in biopharmaceutics[J].Int J Pharm, 2005,289 : 1-30. DOI: 10. 1016/j. ijpharm. 2004.11. 014.
  • 5CROMWELL M E, HILARIO E,JACOBSON F. Protein aggregation and bioprocessing[J]. AAPS J, 2006,8:E572-E579. DOI: 10. 1208/aapsj080366.
  • 6MAHLER H C,FRIESS W, GRAUSCHOPF U, et al. Protein aggregation: pathways,induction factors and analysis[J].. J Pharm Sci, 2009,98 : 2909-2934. DOI : 10. 1002/iDs. 21566.
  • 7GEORGIOU G,VALAX P. Isolating inclusion bodies from bacteria[J].. Methods Enzymol, 1999,309: 48. DOI: 10. 1016/ S0076-6879 (99) 09005-9.
  • 8KATAKAM M,BELI. L N,BANGA A K. Effect of surfactants on the physical stability of recombinant human growth hormone[J]. J Pharm Sei, 1995,84 .. 713-716. DOI.. 10. 1002/jps. 2600840609.
  • 9KREILGAARD L, FROKJAER S, FLINK J M, et al. Effects of additives on the stability of humicola lanuginosa lipase during freeze-drying and storage in the dried solid[J]. J Pharm Sci, 1999,88: 281-290. DOI: 10. 1021/js980399d.
  • 10LIU W R, LANGER R, KLIBANOV A M. Moisture-induced aggregation of lyophilized proteins in the solid state[J]. Bio- technol Bioeng, 1991,37 .. 177-184. DOI.. 10. 1002/bit. 260370210.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部